JAGX Jaguar Health, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
12:38
Jan 16
Jan 16
Bullish JAGX on $18M upfront license and Phase 3 catalyst
Author is bullish on Jaguar Health (JAGX) because its exclusive U.S. license deal for Mytesi and Canalevia-CA1 with Future Pak and Woodward Specialty brings an $18M upfront payment ($16M at closing) and up to $20M in milestones, while Jaguar keeps manufacturing and offloads U.S. commercialization costs. The stated catalyst is management’s Lytham Partners Investor Summit presentation on Jan 15-16 and expected updates on the Phase 3 OnTarget crofelemer trial for CIOB and rare disease pipeline (MVID, SBS), which the author says could produce a sustained trend reversal if progress is shown. Main stated risk: the setup depends on Phase 3 progress, and the author notes the stock has been a roller coaster and short interest ticked up slightly.
HIGH
About JAGX Investor Commentary
Across the available history and selected sources, Buzzberg tracks JAGX (Jaguar Health, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Impossible-Hair1343.